US Stock MarketDetailed Quotes
WTFC Wintrust Financial
- 137.080
- +3.450+2.58%
Close Nov 22 16:00 ET
- 137.360
- +0.280+0.20%
Pre 06:52 ET
9.11BMarket Cap14.37P/E (TTM)
137.325High133.790Low365.89KVolume133.790Open133.630Pre Close49.90MTurnover0.56%Turnover Ratio14.31P/E (Static)66.49MShares137.32552wk High1.52P/B8.98BFloat Cap86.77952wk Low1.75Dividend TTM65.54MShs Float137.325Historical High1.28%Div YieldTTM2.65%Amplitude6.753Historical Low136.385Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Wintrust Financial Stock Forum
Wintrust Financial is gearing up to report its quarterly earnings on Monday, and analysts are anticipating a strong performance. The company is expected to surpass market expectations, potentially triggering a significant bullish run.
The Power of a Strong Earnings Report
A positive earnings report can have a profound impact on a company's stock price. It can transform a relatively unknown or overlooked company into a major m...
Wintrust Financial
Positive Indicators:
+ Strong Regional Economy: Wintrust Financial operates primarily in the Midwest, a region that has shown resilience and growth in recent quarters. This economic strength can directly impact the bank's loan portfolio and deposit base.
+ Increased Lending Activity: Rising interest rates have generally led to increased lending activity, which can boost Wintrust's revenue and net int...
NEWS
Wintrust Financial Corporation and Macatawa Bank Corporation Announce Plans to Merge
Wintrust Financial and Macatawa Bank have announced a merger agreement for Wintrust to acquire Macatawa in an all-stock transaction. Macatawa, with approximately $2.7 billion in assets, will be acquired for an estimated $510.3 million, or $14.85 per share. The transaction is expected to close in the second half of 2024.
• $DBV Technologies (DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics (ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova (MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid (CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax (NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
No comment yet